Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

UPDATE 1-AstraZeneca's combo cancer treatment fails to meet late-stage study main goal

Fri, 06th Mar 2020 07:27

(Adds details on the trial, background on Imfinzi)

March 6 (Reuters) - AstraZeneca Plc said on Friday
its combination treatment for a form of bladder cancer failed to
meet the main goal of improving overall survival in patients
with an advanced form of the disease in a late-stage study.

The safety and tolerability profiles for Imfinzi and the
combination of the drug with tremelimumab were consistent with
previous trials, the British drugmaker said.

Imfinzi is approved for patients with locally advanced or
metastatic bladder cancer previously treated with
platinum-containing chemotherapy in 15 countries, including the
United States.

Imfinzi and tremelimumab belong to the immunotherapy class
of treatments, which strengthen the body's defenses to fight
cancer and tumors.

In 2018, about 550,000 people were diagnosed with bladder
cancer around the world and 200,000 died from the disease,
AstraZeneca said.

Imfinzi is also being tested as a monotherapy and in
combinations including with tremelimumab, as a treatment for
other forms of cancer, including head and neck, liver and
cervical.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; editing by
Uttaresh.V, Bernard Orr)

Related Shares

More News
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the...

27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downt...

27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the w...

27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation readin...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.